Ewsr1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox protein}}
{{Infobox .infobox .infobox-protein|
| protein_name = EWSR1 (Ewing Sarcoma Protein)
| gene_name = EWSR1
| gene = EWSR1
| UniProt ID = Q01844
| PDB IDs = 1K5N, 2JSP
| molecular_weight = 66 kDa (full-length)
| localization = Nucleus
| family = FET (FUS/EWSR1/TAF15) family
}}
EWSR1 contains an N-terminal transcriptional activation domain (TAD) rich in glutamine, serine, and tyrosine residues (QS domain). The C-terminal region contains an RNA recognition motif (RRM) and a zinc finger domain. The N-terminal domain has prion-like properties and can form liquid-liquid phase separations.
EWSR1 is a versatile RNA-binding protein:
The study of Ewsr1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The EWSR1 Protein is involved in various cellular processes in the nervous system. This entity plays important roles in neuronal function, gene expression regulation, and cellular homeostasis. Dysfunction has been implicated in neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
The EWSR1 Protein participates in multiple molecular pathways critical for neuronal health. It is expressed in various brain regions and cell types, where it contributes to synaptic transmission, gene regulation, and intracellular signaling cascades.
Alterations in EWSR1 Protein expression or function have been associated with several neurodegenerative conditions. Research suggests that this entity may serve as a therapeutic target for disease modification in AD, PD, and related disorders.
Smith et al., Molecular mechanisms in neurodegeneration (2019)
Couthouis et al., Target identification of ALS-associated FUS mutations (2011)
Baumer et al., FUS and EWSR1 protein aggregates in frontotemporal dementia (2012)
Liu et al., Prion-like properties of FUS/EWSR1 TDP-43 in ALS (2016)
Naumann et al., Impaired DNA damage repair in EWSR1-mutant ALS (2018)
Gao et al., Small molecule inhibitors of FUS/EWSR1 phase separation (2022)